$CWNM .128 Crown Marketing Patents Approved in Norway

CHAPEL HILL, NC, Feb 05, 2013 (MARKETWIRE via COMTEX) -- Crown Marketing (OTCQB: CWNM) is pleased to announce that patents for its Controlled Drug Delivery Technology have been approved and registered in Norway. Crown is continuing to secure its worldwide patent rights as it pursues novel applications of its drug delivery technology.

About The Company:

Crown's Controlled Drug Delivery Technology (CDDT) is a novel controlled-release technology, harnessing the principles diffusion through precise mathematical formulas. The spectrum and reliability of pharmacokinetic profiles achievable with this technology is superior to currently marketed formulations. Its simple design allows for a high level of flexibility in matching chronotherapeutic requirements. Cost-efficiencies in the commercial manufacturing process, when compared to other drug delivery technologies, may constitute its most important competitive advantage.

The objective of intelligent drug delivery design amounts to maximizing the percent of the time drug plasma levels are within the therapeutic range and avoiding patient exposure to potentially toxic (High) or sub-therapeutic (Low) levels.

Crown's cost-effective application of controlled delivery technologies will play a major role in the expansion of the pharmaceutical, OTC and nutraceuticals industry through our ability to improve on the performance of immediate release products in a manner tangible to manufacturers and consumers.